RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28497782.
- Also identified by DOI 10.1038/ncomms15262 and PMC identifier 5437303.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
NRAS and its effector BRAF are frequently mutated in melanoma. Paradoxically, CRAF but not BRAF was shown to be critical for various RAS-driven cancers, raising the question of the role of RAF proteins in NRAS-induced melanoma. Here, using conditional ablation of Raf genes in NRAS-induced mouse melanoma models, we investigate their contribution in tumour progression, from the onset of benign tumours to malignant tumour maintenance. We show that BRAF expression is required for ERK activation and nevi development, demonstrating a critical role in the early stages of NRAS-driven melanoma. After melanoma formation, single Braf or Craf ablation is not sufficient to block tumour growth, showing redundant functions for RAF kinases. Finally, proliferation of resistant cells emerging in the absence of BRAF and CRAF remains dependent on ARAF-mediated ERK activation. These results reveal specific and compensatory functions for BRAF and CRAF and highlight an addiction to RAF signalling in NRAS-driven melanoma.
Medical subject headings
- Melanoma
- Monomeric GTP-Binding Proteins
- Proto-Oncogene Proteins B-raf
- Proto-Oncogene Proteins c-raf
- ras Proteins